DelveInsight’s, “Glioma Pipeline Insight 2023” report provides comprehensive insights about 190+ companies and 130+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Glioma Pipeline Report

• DelveInsight’s Glioma pipeline report depicts a robust space with 190+ active players working to develop 130+ pipeline therapies for Glioma treatment.
• The leading companies working in the Glioma Market include Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio Inc., BioMimetix, CNS Pharmaceuticals, and others.
• Promising Glioma Pipeline Therapies in the various stages of development include DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.
• December 2023: Day One Biopharmaceuticals Inc. announced a study of Phase 3 clinical trials for DAY101 and Chemotherapeutic Agent. This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
• November 2023: AnHeart Therapeutics Inc. announced a study of Phase 2 clinical trials for Safusidenib. This is a Phase 2, multicenter, open label, two parts, clinical study to evaluate the efficacy, safety, and PK of safusidenib. Patients with recurrent or progressive histologically confirmed IDH1 mutant WHO Grade 2/3 glioma10 outside Japan, will be enrolled in this study. It was divided into 2 parts.
• November 2023: Chimerix announced a study of Phase 3 clinical trials for ONC201. This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
• November 2023: Sumitomo Pharma America Inc. announced a study of early Phase 1 clinical trials for DSP-0390. This is a study of DSP-0390 in patients with recurrent high grade glioma. This study will evaluate the safety and efficacy of DSP-0390 in patients with recurrent high grade glioma.

 

Request a sample and discover the recent advances in Glioma Treatment Drugs @ Glioma Pipeline Outlook Report

 

In the Glioma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioma Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Glioma Overview

A glioma is a tumor that forms in the brain or spinal cord. Neuroglial cells also known as glial cells or glia are quite different from nerve cells. They do not participate directly in synaptic interactions and electrical signaling, although their supportive functions help define synaptic contacts and maintain the signaling abilities of neurons. Glia are more numerous than nerve cells in the brain, outnumbering them by a ratio of perhaps 3 to 1.

 

Find out more about Glioma Treatment Landscape @ Drugs for Glioma Treatment

 

Glioma Emerging Drugs Profile

• Tofacitinib: Pfizer
• Enzastaurin: Denovo BioPharma
• MDNA55: Medicenna Therapeutics, Inc.
• Sym004: Symphogen A/S
• MN-166: MediciNova

 

Glioma Pipeline Therapeutics Assessment

There are approx. 190+ key companies which are developing the therapies for Glioma Disease. The Glioma companies which have their Glioma Disease drug candidates in the most advanced stage, i.e. Phase III include, Denovo BioPharma.

 

DelveInsight’s Glioma pipeline report covers around 130+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Glioma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Glioma Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Learn more about the emerging Glioma Pipeline Therapies @ Glioma Clinical Trials Assessment

 

Scope of the Glioma Pipeline Report

• Coverage- Global
• Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Glioma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio Inc., BioMimetix, CNS Pharmaceuticals, and others.
• Glioma Pipeline Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.

 

Dive deep into rich insights for new drugs for Glioma Treatment, Visit @ Glioma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Glioma Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Glioma Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Enzastaurin: Denovo BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MDNA55: Medicenna Therapeutics, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Zotiraciclib: Adastra Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. RGN6024: Reglagene, Inc.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glioma Disease Key Companies
21. Glioma Disease Key Products
22. Glioma Disease- Unmet Needs
23. Glioma Disease- Market Drivers and Barriers
24. Glioma Disease- Future Perspectives and Conclusion
25. Glioma Disease Analyst Views
26. Glioma Disease Key Companies
27. Appendix

 

For further information on the Glioma Pipeline Therapeutics, reach out @ Glioma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market